Nkarta, which is developing cell therapy treatments for cancer, has emerged from stealth with $114m in a round featuring Novo, Amgen Ventures and SR One.

The drug developer raised nearly $330m earlier this year according to its IPO filing, with $110m being supplied by SoftBank Vision Fund.

Lilly Asia Ventures returned to take part in a series B round led by Access Industries unit Access Biotechnology that took Passage Bio's funding to $226m to date.

Returning investor Kaiser Permanente Ventures contributed to a round that brought on-demand behavioural health app developer Ginger's lifetime funding to $63m.

Renee Ryan and Marianne De Backer have moved on from corporate venturing vehicle Johnson & Johnson Innovation – JJDC for roles at Cala Health and Bayer respectively.

Gyroscope Therapeutics, a dry AMD treatment developer exploiting University of Cambridge research, has secured $61.2m from cornerstone investors Cambridge Innovation Capital and Syncona.

Leveraging University of Glasgow and University of Southern Denmark research, Caldan is targeting a free fatty acid receptor associated with fatty liver disease and type 2 diabetes.

Novartis, Medtronic and SinoPharm will exit the stem cell-based diabetes therapy developer in an acquisition by Vertex Pharmaceuticals.

Novartis, Medtronic and SinoPharm will exit the stem cell-based diabetes therapy developer in an acquisition by Vertex Pharmaceuticals.

UCL and Francis Crick-founded Achilles has raised series B funding at a reported $228m valuation and will now look to advance lung cancer and melanoma treatments.